Logo image of OSA

PROSOMNUS INC (OSA) Stock Fundamental Analysis

NASDAQ:OSA - Nasdaq - US50535E1082 - Common Stock - Currency: USD

0.47  -0.05 (-10.29%)

After market: 0.44 -0.03 (-6.38%)

Fundamental Rating

1

OSA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 503 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of OSA have multiple concerns. While showing a medium growth rate, OSA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

OSA had negative earnings in the past year.
In the past year OSA has reported a negative cash flow from operations.
OSA Yearly Net Income VS EBIT VS OCF VS FCFOSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 -2M -4M -6M -8M -10M

1.2 Ratios

OSA's Return On Assets of -49.44% is on the low side compared to the rest of the industry. OSA is outperformed by 67.18% of its industry peers.
Industry RankSector Rank
ROA -49.44%
ROE N/A
ROIC N/A
ROA(3y)-65.61%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OSA Yearly ROA, ROE, ROICOSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 0 -100 -200

1.3 Margins

OSA has a Gross Margin of 52.38%. This is comparable to the rest of the industry: OSA outperforms 47.18% of its industry peers.
The Profit Margin and Operating Margin are not available for OSA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 52.38%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OSA Yearly Profit, Operating, Gross MarginsOSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 0 20 -20 40 -40 -60

More info and screens

2

2. Health

2.1 Basic Checks

OSA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OSA has about the same amount of shares outstanding.
The debt/assets ratio for OSA has been reduced compared to a year ago.
OSA Yearly Shares OutstandingOSA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 5M 10M 15M
OSA Yearly Total Debt VS Total AssetsOSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 10M 20M 30M

2.2 Solvency

OSA has an Altman-Z score of -11.52. This is a bad value and indicates that OSA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.52, OSA is doing worse than 80.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.52
ROIC/WACCN/A
WACC7.85%
OSA Yearly LT Debt VS Equity VS FCFOSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 10M -10M 20M -20M

2.3 Liquidity

OSA has a Current Ratio of 1.53. This is a normal value and indicates that OSA is financially healthy and should not expect problems in meeting its short term obligations.
OSA has a worse Current ratio (1.53) than 83.08% of its industry peers.
OSA has a Quick Ratio of 1.38. This is a normal value and indicates that OSA is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of OSA (1.38) is worse than 71.79% of its industry peers.
Industry RankSector Rank
Current Ratio 1.53
Quick Ratio 1.38
OSA Yearly Current Assets VS Current LiabilitesOSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

OSA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.77%.
OSA shows a strong growth in Revenue. In the last year, the Revenue has grown by 42.22%.
EPS 1Y (TTM)-28.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-218.18%
Revenue 1Y (TTM)42.22%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%41.4%

3.2 Future

Based on estimates for the next years, OSA will show a small growth in Earnings Per Share. The EPS will grow by 4.66% on average per year.
OSA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 30.56% yearly.
EPS Next Y-101.05%
EPS Next 2Y-25.09%
EPS Next 3Y4.66%
EPS Next 5YN/A
Revenue Next Year41.66%
Revenue Next 2Y33.46%
Revenue Next 3Y30.56%
Revenue Next 5YN/A

3.3 Evolution

OSA Yearly Revenue VS EstimatesOSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
OSA Yearly EPS VS EstimatesOSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OSA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OSA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OSA Price Earnings VS Forward Price EarningsOSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OSA Per share dataOSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.09%
EPS Next 3Y4.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OSA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROSOMNUS INC

NASDAQ:OSA (4/17/2024, 8:17:27 PM)

After market: 0.44 -0.03 (-6.38%)

0.47

-0.05 (-10.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-26 2024-03-26/amc
Earnings (Next)05-10 2024-05-10/amc
Inst Owners0.1%
Inst Owner Change0%
Ins Owners23.16%
Ins Owner Change0%
Market Cap8.17M
Analysts77.14
Price Target2.55 (442.55%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.47%
Min EPS beat(2)-103.84%
Max EPS beat(2)96.91%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.37%
Min Revenue beat(2)-0.46%
Max Revenue beat(2)7.21%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)25%
PT rev (3m)25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.08%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.24%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.22%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.32
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-0.91
OCFYN/A
SpS1.47
BVpS-1.25
TBVpS-1.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -49.44%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 52.38%
FCFM N/A
ROA(3y)-65.61%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 187.18%
Cap/Sales 11.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.53
Quick Ratio 1.38
Altman-Z -11.52
F-Score4
WACC7.85%
ROIC/WACCN/A
Cap/Depr(3y)54.81%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.39%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-218.18%
EPS Next Y-101.05%
EPS Next 2Y-25.09%
EPS Next 3Y4.66%
EPS Next 5YN/A
Revenue 1Y (TTM)42.22%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%41.4%
Revenue Next Year41.66%
Revenue Next 2Y33.46%
Revenue Next 3Y30.56%
Revenue Next 5YN/A
EBIT growth 1Y-208.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-51.46%
EBIT Next 3Y11.19%
EBIT Next 5YN/A
FCF growth 1Y-135.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-121.17%
OCF growth 3YN/A
OCF growth 5YN/A